DK0469017T3 - Ekspression af humane apolipoproteiner AI-Milano i gær - Google Patents

Ekspression af humane apolipoproteiner AI-Milano i gær

Info

Publication number
DK0469017T3
DK0469017T3 DK90906181.4T DK90906181T DK0469017T3 DK 0469017 T3 DK0469017 T3 DK 0469017T3 DK 90906181 T DK90906181 T DK 90906181T DK 0469017 T3 DK0469017 T3 DK 0469017T3
Authority
DK
Denmark
Prior art keywords
yeast
expression
milan
human apolipoproteins
apolipoprotein
Prior art date
Application number
DK90906181.4T
Other languages
English (en)
Inventor
Alessandro Sidoli
Francisco Baralle
Cesare Sirtori
Guido Franceschini
Original Assignee
Cesare Sirtori
Guido Franceschini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cesare Sirtori, Guido Franceschini filed Critical Cesare Sirtori
Application granted granted Critical
Publication of DK0469017T3 publication Critical patent/DK0469017T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90906181.4T 1989-04-20 1990-04-17 Ekspression af humane apolipoproteiner AI-Milano i gær DK0469017T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8920226A IT1229996B (it) 1989-04-20 1989-04-20 Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.

Publications (1)

Publication Number Publication Date
DK0469017T3 true DK0469017T3 (da) 1994-10-03

Family

ID=11164927

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90906181.4T DK0469017T3 (da) 1989-04-20 1990-04-17 Ekspression af humane apolipoproteiner AI-Milano i gær

Country Status (10)

Country Link
EP (1) EP0469017B1 (da)
JP (3) JP3082941B2 (da)
AT (1) ATE107360T1 (da)
AU (1) AU641389B2 (da)
CA (1) CA2053288C (da)
DE (1) DE69010000T2 (da)
DK (1) DK0469017T3 (da)
ES (1) ES2054353T3 (da)
IT (1) IT1229996B (da)
WO (1) WO1990012879A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
FR2686605B1 (fr) * 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
ATE236925T1 (de) * 1996-09-11 2003-04-15 Pharmacia Ab Verfahren zur reinigung von apolipoproteinen
WO1998011140A1 (en) * 1996-09-11 1998-03-19 Pharmacia & Upjohn Ab A process for purifying apolipoproteins and a composition for use in the process
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
NZ532217A (en) * 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
WO2005051413A2 (en) * 2003-11-26 2005-06-09 Novartis Ag Disease associated genes
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
CN1320119C (zh) * 2004-12-09 2007-06-06 复旦大学 人载脂蛋白ApoAⅠ在毕赤氏酵母胞内表达的方法
US7759315B2 (en) 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
ES2442594T3 (es) 2007-03-01 2014-02-12 Csl Limited Tratamiento de la disfunción endotelial en pacientes diabéticos
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
US20130310304A1 (en) * 2010-06-15 2013-11-21 Matthew C. Lawyer Compositions and methods for the treatment of atherosclerosis
FR2961814B1 (fr) * 2010-06-29 2014-09-26 Isp Investments Inc Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
LT2673296T (lt) 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
WO1987002062A1 (en) * 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
GB8712540D0 (en) * 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
DK463887D0 (da) * 1987-09-07 1987-09-07 Novo Industri As Gaerleader

Also Published As

Publication number Publication date
ES2054353T3 (es) 1994-08-01
EP0469017B1 (en) 1994-06-15
JP2004339229A (ja) 2004-12-02
IT8920226A0 (it) 1989-04-20
ATE107360T1 (de) 1994-07-15
CA2053288C (en) 2006-06-06
IT1229996B (it) 1991-09-20
DE69010000D1 (de) 1994-07-21
WO1990012879A3 (en) 1991-05-16
CA2053288A1 (en) 1990-10-21
JPH05504673A (ja) 1993-07-22
EP0469017A1 (en) 1992-02-05
JP3082941B2 (ja) 2000-09-04
JP2000212098A (ja) 2000-08-02
DE69010000T2 (de) 1994-09-22
AU641389B2 (en) 1993-09-23
AU5424590A (en) 1990-11-16
WO1990012879A2 (en) 1990-11-01
JP3845101B2 (ja) 2006-11-15

Similar Documents

Publication Publication Date Title
ATE107360T1 (de) Expression von menschlichen apolipoproteinen ai- milano in hefe.
DK0526544T3 (da) Terapeutiske anvendelser af actinbindende forbindelser
DE58900776D1 (de) Verfahren zur herstellung von apolipoproteinen aus blutplasma- oder serumfraktionen.
DK221589D0 (da) Fremgangsmaade til at udtrykke ikke-gaerprotein i en gaervaert og transformeret gaervaert
MX172309B (es) Mejoras a material encogido-unido elastico compuesto
DK0400958T3 (da) Levende vacciner
LV10203B (en) Skin test and test kit for aids
BR8902172A (pt) Processo de e aparelho para determinar parametros acusticos para emprego com uma protese auditiva
FI962613L (fi) Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi
NO920671L (no) Fremgangsmaate for aktivering av rekombinante proteiner
DK230590A (da) Sproejte til brug ved kataraktkirurgi
DE69101634D1 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
AU6110490A (en) 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases
FI924746A7 (fi) Kohydrolyysimenetelmä uusien uutteiden valmistamiseksi hiiva- ja ei-hi ivaproteiineista
NO180181C (no) Fremgangsmåte for fremstilling av et is-kjernedannende protein, plasmider og bakteriestammer
NO180636C (no) Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1
DE69129747D1 (de) In lösung bringen von proteinen in aktiver form
NO170661C (no) Anordning for behandling av yngel paa tidlige utviklingsstadier
DE69630197D1 (de) Erhöhte stabilität von azadirachtin enthaltenden festen zubereitungen
NO925048D0 (no) Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
KR890700661A (ko) 효모에 의한 플라즈모듐 팔시파룸의 외주포자소체 단백질의 발현
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
AU3328289A (en) Expression of hepatitis B2 pres protein in methylothrophic yeasts
DE69126563D1 (de) Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia
ATE153379T1 (de) Expression von proteinsüssmitteln in hefe